Drilldown: Medicines
Use the filters below to narrow your results.
generic: (Click arrow to add another value)
brand:
classes:
mechanism:
None (1) ·
Human IgG1 monoclonal antibody targeting aggregated forms of amyloid-β (Aβ), soluble oligomers and insoluble fibrils. Reduces Aβ plaque burden on PET imaging via Fc-mediated microglial clearance. Whether plaque reduction translates to clinical benefit is the core controversy. (1) ·
Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) ·
Humanized IgG2 monoclonal antibody binding the CGRP receptor (not the peptide); blocks CGRP-mediated vasodilation and nociceptive signaling (1) ·
Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1)
uses:
Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. (1) ·
Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1) ·
Preventive treatment of migraine in adults (episodic and chronic) (2) ·
Preventive treatment of migraine in adults; episodic cluster headache (1)
starting dose:
225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) ·
70 mg SC monthly; may increase to 140 mg monthly (1) ·
700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance (1) ·
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1) ·
Was 1 mg/kg IV q4w × 2, then 3 mg/kg × 2, then 6 mg/kg × 2, then 10 mg/kg q4w (1)
preparations:
fda max:
routes: (Click arrow to add another value)
onset:
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 5 results in range #1 to #5.